{"id":"W1764111892","doi":"10.1080/00325481.2015.998987","title":"Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis","year":2015,"lang":"en","type":"article","venue":"Postgraduate Medicine","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Alirocumab; PCSK9; Medicine; Evolocumab; Kexin; Placebo; Internal medicine; Adverse effect; Gastroenterology; Statin; Pharmacology; Endocrinology; Lipoprotein; Cholesterol; LDL receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002222641,0.0004771463,0.002015732,0.0006630087,0.0002135439,0.00001417294,0.0001916513,0.0001911984,0.0001729006],"category_scores_gemma":[0.0007867641,0.0003490107,0.0003865682,0.001393239,0.0004940014,0.0001234996,0.0001485394,0.0004277601,0.00001396891],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001564851,"about_ca_system_score_gemma":0.0005258849,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006018776,"about_ca_topic_score_gemma":0.0001423344,"domain_scores_codex":[0.9958027,0.000288091,0.001136128,0.0007435755,0.001438609,0.0005908883],"domain_scores_gemma":[0.9966486,0.00006847347,0.000390774,0.001116737,0.0008467349,0.0009286643],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.08494627,0.01551792,0.06557039,0.006027604,0.0546887,0.005064054,0.02306005,0.0001009865,0.4287255,0.002949589,0.01155021,0.3017988],"study_design_scores_gemma":[0.3508873,0.09054585,0.3586806,0.004653726,0.07886194,0.00252135,0.003878796,0.009971608,0.04313171,0.001330977,0.05192275,0.00361332],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.983611,0.007422028,0.0005678821,0.005764891,0.0001699919,0.001736827,0.0000618878,0.0001035797,0.0005618996],"genre_scores_gemma":[0.996072,0.0004314014,0.0004394915,0.0005695288,0.0005268799,0.0000209623,0.001097958,0.00005934558,0.0007824238],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3855937,"threshold_uncertainty_score":0.9998962,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03230265787129456,"score_gpt":0.3366144563576577,"score_spread":0.3043117984863632,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}